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INTRODUCTION
Heart failure (HF) continues to be an enormous public health problem, despite the many
advances in its pharmacotherapy over the past 25 years, with a prevalence of 5.7
million individuals affected and an incidence of over 500,000 new cases annually.1 The
relevance of the natriuretic peptide (NP) system, particular BNP, is well known in terms
of HF pathophysiology,2, 3 diagnosis,4 prognosis,5 and therapy.6, 7

However, the full

impact of testing, and particularly modulating, the NP pathway remains unclear. Part of
this difficulty in how to harness this pathway for the benefit of patients is due to
substantial inter-individual variability in function of the NP pathway. Not only are the
optimal diagnostic and prognostic thresholds uncertain and varying,8 but the response
to extrinsic NP is highly variable with potential for adverse effects and unclear
therapeutic range.9-11 Better understanding of the variability in this important pathway is
critical not only because it continues to be explored as a method for personalized
therapy, but because there are numerous current (nesiritide, carperitide) and
investigational therapeutics (ularitide,12 CDNP13) targeting it.
Genetic variation may hold a key to better understanding this individual
variability.14 BNP levels are known to be heritable,15 and specific genetic variants in NP
pathway genes have been associated with hypertension,16 BNP level and test
performance,17, 18 and intracardiac filling pressures,19. Despite these observations, a
lack of systematic knowledge remains with respect to the effects of NP genetic
variability on the production of relevant protein end-products. Better understanding of
this variability may allow it to be used to personalize therapy by identifying differences in
how patients metabolize and respond to NPs. Relevant to HF, NPs act primarily (Figure

1) by binding to two membrane-spanning receptors called natriuretic peptide receptor
(NPR) A and NPRB, which are guanylate cyclases resulting in cyclic guanlyate mono
phosphate (cGMP) production. The latter is thought to be the key second messenger
mediating the NP effects. Active NP is broken down by neutral endopeptidase (aka
membrane metallo-endopeptidase (MME)), and taken up by NPRC, another receptor
which lacks guanylate cyclase function. These four proteins are produced by the genes
NPR1, NPR2, MME and NPR3 respectively. The purpose of this study was to
systematically study sequence variants in these genes, quantify gene expression and
protein abundance of each product in relevant human tissue samples in order to
evaluate important associations.

METHODS
The study was approved by the Henry Ford Hospital Institutional Review Board. DNA,
RNA, and tissue samples from human kidney (n=77) were obtained via the Alvin J.
Siteman Cancer Center at Washington University School of Medicine and BarnesJewish Hospital in St. Louis, Mo., Tissue Procurement Core lab, under approval from
Washington University Institutional Review Board and with informed consent. Kidney
was chosen as target tissue because each of the four candidate genes and proteins
(natriuretic peptide receptor (NPR1), NPR2, NPR3 and membrane metalloendopeptidase (MME)) are expressed there. 100 samples were originally requested, to
be distributed evenly among African Americans vs Whites and men vs. women. In total
103 suitable samples were tested.

Genotyping, Gene Expression, and Protein Quantitation
DNA samples were genotyped using a custom Illumina Goldengate 1536-plex
array which contained candidate-gene coverage relevant to HF including focused
attention on the four genes of interest. Single nucleotide polymorphisms (SNPs) were
chosen for the array by attempting to include all coding variants, and then adding all
non-coding variants to capture alleles with MAF >0.1 prevalence in Caucasians or
Africans within the gene regions of interest. After processing requirements for the
Goldengate technology and quality control of genotyping we were left with 118 SNPs in
the four genes of interest for this study. Genotyping was auto clustered and then
individual SNPs were reviewed manually. Call rates for all samples were >90%. mRNA

expression was quantified for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(comparator), NPR1, NPR2, NPR3, and MME using real-time reverse transcriptase
polymerase chain reaction (RT-PCR) performed in duplicate for each sample. To
determine the concentration of the protein targets, tissue samples were made into
lysates and then assayed using double antibody sandwich Enzyme Linked
Immunosorbant Assays (ELISA). The samples were homogenized by suspending in 1ml
phosphate buffered saline solution and then sonicated. The resulting suspension was
centrifuged for 5 minutes at 5000g. The supernatant was then removed and stored at 80°C for testing. The concentration of each marker was assayed using commercially
available assay kits (Uscn Life Science Inc., Missouri City, Texas) according to
manufacturer protocol and using standard curves and software. Total protein
concentrations were determined by using a modified Lowry Protein Assay. The ratio of
target protein to total protein was reported and tested for association with genotype or
RNA quantity.

Statistical Analysis
Following log transformation of the protein and RNA expression data, linear regression
was used to test for the association of each SNP with RNA and protein quantity under
an additive genetic model. A principal components (PC) based method was also used
to capture the underlying correlation structure within each locus and test the association
of overall gene variation with RNA and protein quantity. We selected top PCs that
explain at least 80% of the variation as the gene representation and the PCs were used

as covariates in the linear regression to test for association of SNPs with RNA and
protein expression. All models were adjusted for gender and race. P values <0.05
were considered of possible interest in this exploratory study. To account for multiple
comparisons we also utilized the method of Hochberg20 and considered findings with
false discovery rate (FDR) <0.05 significant.

RESULTS
Genotype was obtained in 7 loci in NPR1, 18 loci in NPR2, 53 loci in NPR3, and 40 loci
in MME. Each site was tested individually for association with RNA and protein quantity
with summary results shown in Figure 1. In terms of gene expression, several variants
in MME and NPR3 showed crude associations with unadjusted p<0.05. For there were
four SNPs in MME (rs1025192, rs1436630, rs10513469 and rs1816558) and one in
NPR3 (rs696831) that showed suggestive associations with RNA levels (p≤0.05).
However, none of these met significance once adjusted for FDR. There were no
significant associations of genotype with gene expression for NPR1 or NPR2.
Considering protein quantitation, we assayed each sample for the ratio of specific
protein of interest (NPR1, NPR2, NPR3, and MME) to total protein, and then tested the
association of this ratio (i.e. the target protein abundance) with genotypes within the
corresponding gene. There were no significant associations of genotype with NPR1
and protein abundance. There were two sequence variants in NPR3 (rs696836,
rs2062708) and one in MME (rs3773895) with significant associations of genotype with
protein quantity; however these did not withstand adjustment for multiple comparisons.
Interestingly, eleven SNPs in NPR2 were significantly associated with protein
expression (p<0.05) and this association persisted after controlling for FDR at 0.05.
Boxplots of protein abundance by genotype for each significant loci is shown in Figure
2. There were no SNPs associated with both RNA and protein expression in any of the
candidate genes.

RNA and Protein quantity poorly correlated with each other; NPR1 and MME
showed weak but statistically significant positive correlations (Pearson’s correlation
coefficient=0.23 and 0.26, p = 0.04 and 0.03, respectively) while NPR2 and NPR3 did
not (Figure 3). The PC analyses were broadly consistent with the individual SNP
analysis above. PC1 of NPR2 (which accounted for 71% of genetic variability) was the
only significant association of genetic variation with protein abundance (p=0.04). The
factor loadings for PC1 (data not shown) suggest that it is mainly determined by the
same 11 SNPs above, which each had equally high weight. We also found an
association between PC5 of NPR3 and its gene expression (p=0.0084). The loadings of
SNPs indicates that PC5 is highly contributed by SNPs rs764124, rs1847018,
rs10057069, rs6889608, rs696831, and rs2302954.

DISCUSSION
Our systematic interrogation of genotype, gene expression, and protein quantity
correlations reveals that genetic variation may play a role in determining protein
abundance for NPRB. Interestingly, these associations did not seem to occur via
changes in gene expression, which did not correlate to either protein quantity or
genotype for NPR2. The other genes tested did not show indications of genetic
variation importantly effecting gene expression or protein abundance in kidney.
Although there have been numerous studies examining the relationship of NP
pathway genetic polymorphisms to clinical phenotypes, corresponding functional data is
less available. While our study is exploratory and descriptive in nature, these data add
to the existing knowledgebase by describing the potential physiologic impact of
candidate variants on gene and protein expression, and prioritizing these for future
investigation. These data could be used to buttress the biologic plausibility of previously
described clinical phenotypes, and in terms of prioritizing variants for subsequent
clinical interrogation NPR2 appears to be the best target. While there were some
interesting genotype: gene expression associations for other pathway candidate genes,
these did not meet significance and did not correlate to protein abundance.
There are several limitations of this study that should be considered when
evaluating these data. First is the relatively small sample size, limiting the power
somewhat; for example we estimate 90% power to detect at least 2.5-fold variation and
minor allele frequency of 0.2. While high-throughput methods are available for DNA
sequencing, real-time PCR, and more importantly protein quantification, remain labor

intensive and impractical for very large sample sizes. Our sample size was designed to
accommodate this limitation and indentify robust variation, not very subtle changes in
protein or gene expression. Second is that we examined only kidney tissue, and cannot
deduce information about gene and protein expression in other tissues that may be of
interest such as cardiac tissue. However, kidney was felt to be the best choice when
considering the NP pathway physiologically, and as it pertains to pharmaceuticals (such
as recombinant NPs or endopeptidase inhibitors), because it is a key location for both
clearance and effect of NPs, and there is expression of all the candidate genes.
Another potential concern is that renal tissue is not homogenous; how whether and how
this impacted on our findings is unknown. Finally, we have focused on protein
quantitation and have not tested protein function. This remains important investigation
for follow up studies.

ACKNOWLEDGEMENTS
We thank the Alvin J. Siteman Cancer Center at Washington University School of
Medicine and Barnes-Jewish Hospital in St. Louis, Mo., for the use of the Tissue
Procurement Core, which provided tissue, DNA, and RNA isolation services. The
Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant
#P30 CA91842.

CITATIONS
1.
2.

3.

4.

5.

6.
7.

8.

9.

10.

11.
12.

American Heart Association. Heart Disease and Stroke Statistics - 2009 Update. Dallas, Texas:
American Heart Association; 2009.
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a
biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic
left ventricular dysfunction. Am Heart J. 1998;135(5 Pt 1):825-832.
Ellmers LJ, Scott NJ, Piuhola J, Maeda N, Smithies O, Frampton CM, Richards AM, Cameron VA.
Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol
Endocrinol. 2007;38(1-2):245-257.
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB,
Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R,
Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the
emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordonez-Llanos J, Martinez P, Cinca J, Valdes M,
Januzzi JL, Bayes-Genis A. Usefulness of clinical and NT-proBNP monitoring for prognostic
guidance in destabilized heart failure outpatients. Eur Heart J. 2008;29(8):1011-1018.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:
a randomized controlled trial. Jama. 2002;287(12):1531-1540.
Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz
MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic
peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N
Engl J Med. 2000;343(4):246-253.
Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T,
Storrow AB, Abraham WT, Wu AH, Steg G, Westheim A, Knudsen CW, Perez A, Kazanegra R,
Bhalla V, Herrmann HC, Aumont MC, McCullough PA. Impact of age, race, and sex on the ability
of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the
Breathing Not Properly (BNP) multinational study. Am Heart J. 2004;147(6):1078-1084.
O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM,
Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams
KF, Jr., Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R,
Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker
GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol
RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL,
Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA,
Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart
failure. N Engl J Med. 2011;365(1):32-43.
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment
with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled
trials. Jama. 2005;293(15):1900-1905.
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide
in patients with acutely decompensated heart failure. Circulation. 2005;111(12):1487-1491.
Luss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS, Forssmann WG, Hamdy
AM, Meyer M. Renal effects of ularitide in patients with decompensated heart failure. Am Heart
J. 2008;155(6):1012 e1011-1018.

13.

14.
15.
16.

17.
18.

19.

20.
21.

McKie PM, Sangaralingham SJ, Burnett JC, Jr. CD-NP: an innovative designer natriuretic peptide
activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep.
2010;7(3):93-99.
Lanfear DE. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev.
2010;15(3):219-228.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Corey D, Leip EP, Vasan RS. Heritability and genetic
linkage of plasma natriuretic peptide levels. Circulation. 2003;108(1):13-16.
Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S,
Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X,
Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of
common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.
Nat Genet. 2009;41(3):348-353.
Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natiuretic
peptide pathway affects BNP levels. Cardiovasc Drugs Ther. 2007;21(1):55-62.
Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, Mahoney DW, Slusser JP, Heublein DM,
Redfield MM, Rodeheffer RJ, Olson TM, Burnett JC, Jr. The Effect of the Brain-Type Natriuretic
Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays.
Mayo Clin Proc. 2011;86(3):210-218.
Lanfear DE, Stolker J, Marsh S, Rich MW, McLeod HL. Natriuretic Peptide Receptor 3 (NPR3)
Genotype Modulates the Relationship between B-Type Natriuretic Peptide (BNP) and Left
Ventricular End-Diastolic Pressure. Therapy. 2006;3(6):765-771.
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior
genetics research. Behavioural brain research. 2001;125(1-2):279-284.
Stoupakis G, Klapholz M. Natriuretic peptides: biochemistry, physiology, and therapeutic role in
heart failure. Heart Dis. 2003;5(3):215-223.

FIGURE LEGENDS
Figure 1. Graphical presentation of p-values for testing SNP association with gene
expression and protein expression for NPR1, NPR2, NPR3, MME
Figure 2. Target protein abundance by genotype in the 11 statistically significant SNPs
of NPR2 (FDR≤0.05).
Figure 3. Scatter plot showing the relation between RNA and protein quantity for each
gene.
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Figure 1.

Figure 2. Target protein abundance by genotype for NPR2 (loci with FDR≤0.05). (0,1,2)
represents the additive coding of the number of copies of the minor allele.
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Figure 3. Scatter plot showing the relation between RNA and protein quantity for each
gene. Solid curve represents the smooth fit to better visualize the trends. The fit was
generated using locally weighted scatter plot smoother (LOWESS).
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